Hyperscience

Hyperscience is a New York-based company specializing in enterprise AI solutions, focusing on automating document processing to enhance operational efficiency across various sectors. Founded in 2014 and headquartered in New York, US, Hyperscience develops an AI platform that automates document processing. The company has raised a total of USD 93. 88 mn through multiple funding rounds, with the most recent Series E round occurring on December 17, 2021, co-led by Bessemer Venture Partners, Global Founders Capital, Stripes, and Tiger Global Management.

CEO Andrew Joiner leads the company as it continues to focus on expanding its service offerings and increasing its market presence. Hyperscience offers an enterprise AI platform called Hypercell®, which automates document processing for a range of documents, from simple forms to complex files. Utilizing machine learning, the platform converts unstructured and semi-structured data into high-quality, actionable information. Serving clients in government, healthcare, finance, and insurance sectors—including the U.

S. Social Security Administration and American Express—Hyperscience aims to enhance workflow efficiency globally. Hyperscience operates on a subscription-based revenue model for its Hypercell® platform, where clients pay for access based on their document processing needs. This B2B model focuses on large enterprises and government agencies, utilizing a tiered pricing structure that accommodates varying document volumes and complexities.

The company has established strong revenue streams through long-term contracts with key clients, highlighting its commitment to meeting diverse operational requirements. Following its Series E funding of USD 93. 88 mn in December 2021, Hyperscience plans to invest further in talent acquisition and research and development, both organically and through strategic acquisitions. The company is focused on expanding its market presence in North America, Europe, and the Asia-Pacific region by developing new products and enhancing existing offerings.

Specific product launches and timelines have not been disclosed, but the recent funding will play a pivotal role in supporting these strategic initiatives.